SCM
IONS icon

Sigma Capital Management’s Ionis Pharmaceuticals IONS Stock Holding History

Sigma Capital Management’s Portfolio IONS Stock Details IONS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q3 		– Sell
-25,000
Closed -$672K – 320
2013
Q2 		$672K Buy
+25,000
New +$532K 0.03% 211

Other funds holding IONS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Artisan Partners
Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return
BB
BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
WRF
Waddell & Reed Financial Overland Park, Kansas $48.6B AUM 84.78% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Sigma Capital Management's IONS Position: Q3 2013 in Review

Sigma Capital Management sold out of Ionis Pharmaceuticals (IONS) in Q3 2013, closing a stake of 25,000 shares — an estimated $672K sold.

Sigma Capital Management first reported a position in IONS in Q2 2013 and held it in 1 quarter. The position peaked at $672K in Q2 2013. 204 funds tracked by Wall St. Rank hold IONS as of Q3 2013.

  • Sigma Capital Management reported no remaining Ionis Pharmaceuticals position as of Q3 2013 after selling out during the quarter.
  • Sigma Capital Management sold 25,000 Ionis Pharmaceuticals shares in Q3 2013, an estimated $672K.
  • Sigma Capital Management first reported a position in Ionis Pharmaceuticals in Q2 2013 and held it in 1 quarter.
  • Sigma Capital Management's Ionis Pharmaceuticals position peaked at $672K in Q2 2013.
  • 204 funds tracked by Wall St. Rank held Ionis Pharmaceuticals as of Q3 2013.

Based on Sigma Capital Management's 13F filing for Q3 2013, filed 14 Nov 2013.